Back to Search Start Over

Dematin inhibits glioblastoma malignancy through RhoA-mediated CDKs downregulation and cytoskeleton remodeling.

Authors :
Wang, Mengying
Chen, Binghong
Zhang, Wenrui
Zhang, Fengchen
Qiu, Yongming
Lin, Yingying
Yang, Shaofeng
Source :
Experimental Cell Research. Aug2022, Vol. 417 Issue 1, pN.PAG-N.PAG. 1p.
Publication Year :
2022

Abstract

Glioblastoma multiforme (GBM) is well known as a highly aggressive brain tumor subtype. Here, we show that overexpression (OE) of dematin actin-binding protein (DMTN) inhibits GBM proliferation and invasion by affecting cell cycle regulation and actin remodeling, respectively. RT–qPCR, western blotting, and immunohistochemical (IHC) staining demonstrated a significant reduction in DMTN expression in gliomas, especially in high-grade gliomas (HGG) compared with normal brains, which correlates with worse survival in HGG patients. Functional studies revealed inhibitory effects of DMTN on tumor proliferation and migratory capacities. The attenuation in tumor proliferative ability upon DMTN OE was accompanied by RhoA suppression and CDK1, CDK2, CDK4, and cyclin D1 downregulation, while RhoA rescue restored the proliferative phenotype. Meanwhile, overexpression of DMTN produced profoundly disorganized stress fibers, which led to impaired tumor invasion. Furthermore, DMTN overexpression produced substantial suppression of tumor growth upon subcutaneous and intracranial implantation in mice, and this was accompanied by significantly reduced vinculin expression and Ki67 positivity. Taken together, these findings demonstrate the role of DMTN in regulating GBM cell proliferation, actin cytoskeleton, and cell morphology and identify DMTN as a vital tumor suppressor in GBM progression. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00144827
Volume :
417
Issue :
1
Database :
Academic Search Index
Journal :
Experimental Cell Research
Publication Type :
Academic Journal
Accession number :
157217684
Full Text :
https://doi.org/10.1016/j.yexcr.2022.113196